Vision Risks Associated with GLP-1 Medications Under Investigation
Click to Enlarge
A recent study published in JAMA Ophthalmology highlights potential vision risks associated with GLP-1 medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound). Conducted by researchers, including a neurologist from the University at Buffalo, the study explores cases of sudden vision loss linked to these drugs. Nine patients experienced conditions like nonarteritic anterior ischemic optic neuropathy (NAION), a condition caused by insufficient blood supply to the optic nerve, resulting in partial and often permanent vision loss.
While these cases remain rare, concerns are rising as the use of these medications, primarily for diabetes and weight loss, continues to grow. The patients studied had other health conditions, such as diabetes and cardiovascular issues, which may independently increase the risk of vision problems. Researchers are investigating whether the rapid blood glucose reductions caused by these drugs could exacerbate these risks.
The study emphasizes the importance of prompt action if patients experience vision changes while taking these medications. Physicians should encourage patients reporting blurred or lost vision to consult an ophthalmologist immediately. Patients should not discontinue medication without consulting their healthcare provider, as GLP-1 medications provide significant benefits for managing diabetes and obesity.
The researchers and the American Academy of Ophthalmology are advocating for a post-marketing survey to better assess the prevalence of these ocular side effects. This initiative aims to provide more straightforward guidance to physicians and patients regarding the safe use of these increasingly popular medications.
Ophthalmic complications in patients on antidiabetic GLP-1 medications are concerning neuro-ophthalmologists (Goldbaum, UBNOW, 2/7).
